Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272853 | 0.81 | — | — | |
| SCHEMBL19542913 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL19543109 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL19543141 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL19542885 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL19542911 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL19542898 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL13698413 | 0.78 | POLB (0.40) | POLBKDM4EGAATHRBRECQL | |
| SCHEMBL15561512 | 0.76 | POLB (0.33) | POLB | |
| SCHEMBL8931381 | 0.70 | CYP1A2 (0.41) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3892621-B1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-09-18 | — | — | EP | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-111434662-B | Haloallylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TransThera Sciences (Nanjing), Inc (CN) | 2022-03-17 | — | — | US | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| EP-3892621-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180009830-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2018-01-11 | — | — | US | disclosed |
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| US-20160368894-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-12-22 | — | — | US | disclosed |
| US-9440953-B2 | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-09-13 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| US-20160176843-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-06-23 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | POLB 3715/4885KDM4E 3777/4885GAA 2675/4885 |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | ADRA1D, ADRA1A, VAPA | POLB 3715/4885KDM4E 3777/4885GAA 2675/4885 |
| US-20160176843-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | CHIA, CHIT1, CMA1 | POLB 3194/4885KDM4E 3426/4885GAA 110/4885 |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | POLB 52/4885KDM4E 1517/4885GAA 222/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | POLB 105/4885KDM4E 810/4885GAA 148/4885 |
| US-20160368894-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | CHIA, CHIT1, CMA1 | POLB 3194/4885KDM4E 3426/4885GAA 110/4885 |
| US-20180009830-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | POLB 2708/4885KDM4E 1748/4885GAA 175/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | POLB 44/4885KDM4E 884/4885GAA 706/4885 |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | POLB 2109/4885KDM4E 2969/4885GAA 95/4885 |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | POLB 3655/4885KDM4E 1102/4885GAA 3605/4885 |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, THRA, TSHR | POLB 3188/4885KDM4E 4301/4885GAA 3664/4885 |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | PTMS, RSU1, QSOX1 | POLB 4277/4885KDM4E 2817/4885GAA 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.